Evotec has been a leader in drug discovery and development for over 30 years, offering end-to-end solutions from target identification to clinical trials. Their innovative approach leverages deep disease understanding, cutting-edge technologies, and tailored solutions, supporting collaborations through standalone services, integrated programs, or strategic partnerships to create impactful medicines.
GreyRigge Associates is a global biotech partner delivering consultancy, management expertise and training across the entire product development journey. Our extensive biopharmaceutical industry experience and pragmatic, agile approach enables transformational success by accelerating our clients’ medicines to market.
Our new tagline “Chemistry that delivers” captures the core of our offer: deep expertise in synthetic chemistry and scale-up, applied with rigour and purpose to deliver reliable outcomes. It speaks to our chemistry-first approach and our ability to support science-led organisations across pharmaceuticals, diagnostics, and advanced materials, not just in theory, but in practice. Just as importantly, HFR remains a highly collaborative partner. Our director-led model and long-standing relationships mean you work directly with experienced chemists who understand your challenges and are invested in your success. That hands-on partnership continues to be central to how we operate.
HistologiX is a leading GLP/GCP compliant CRO supporting tissue based evaluation of your biomarkers; they help you visualise and understand what your drug or device is doing to your key biomarkers at the cellular and tissue level. Their experienced scientific team work as an extension of your in-house team and provide specialist histology, immunohistochemistry (IHC) including multiplex immunofluorescence (IF), multiplex in situ hybridisation (ISH) using RNAScope, digital pathology and image analysis services.
hVIVO plc (Ticker: HVO) is a science led drug development partner purpose-built to meet the growing complexity of modern clinical research. The Company operates an integrated end-to-end ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials.
With industry‑leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other high‑growth therapeutic areas, hVIVO supports a diverse global client base that includes seven of the world’s ten largest biopharmaceutical companies. Its London quarantine facilities are the largest purpose‑built human challenge units in the world, complemented by additional early‑phase clinical capacity in Germany and a specialist consulting team providing strategic, regulatory, and biometry expertise.
The Company’s integrated approach delivers a seamless pathway from preclinical planning through early proof‑of‑concept, supported by continuous patient recruitment through FluCamp and a network of outpatient clinical sites for Phase II and III studies. By unifying scientific insight, operational control, and advanced laboratory capabilities, hVIVO provides sponsors with the clarity, speed, and reliability required to advance new medicines with confidence.
IDEA is passionate about getting innovative products to patients with unmet needs and we particularly enjoy putting our full weight of innovative thinking and regulatory expertise behind innovative medicine.
Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.
Emerging advanced therapies such as CAR-T and gene therapies have the potential to cure previously intractable conditions with a single infusion. Unfortunately, these incredible treatments remain out of the reach of many due to current vector technology limiting efficacy, quality, and manufacturing viability.
Lentitek has a unique manufacturing technology that can significantly improve the production quality of the lentivirus vector used in advanced therapies and enable new applications such as in-vivo CAR-T and armoured CARs. Additionally, the improvement in manufacturing quality can lead to higher yields and improved product potency.
MediWales is the life science network and representative body for Wales. An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.
MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally.
